 |
|
|
|
|
| |
|
- Valeant unveils Diastat® AcuDial™ for rapid, at-home treatment of epileptic seizures
- Valeant sells manufacturing facility in Bryan, Ohio
- Valeant initiates Phase 3 clinical trials for its epilepsy candidate retigabine
- Valeant reports positive interim data from pradefovir mesylate Phase 2 study
- Redesigned Migranal Delivery System introduced at the American Headache Society
- Michael Karin, Ph.D., appointed to Valeant Scientific Advisory Board
- Valeant signs agreement with Courteney Cox to represent Kinerase skin care line and distributes line to high-end retailer Sephora
- Tasmar® launches in the European Union
- Valeant acquires Xcel Pharmaceuticals, expanding Valeant's neurology franchise to include migraine treatment Migranal®, epileptic seizure treatment Diastat® and epilepsy treatment candidate retigabine
- Valeant completes public offering of 7.2 million shares
- Valeant announces advancement of research and development funding to accelerate taribavirin Phase 3 clinical trials
- Timothy T. Tyson appointed President and Chief Executive Officer of Valeant
|
|
|
|
